The des-?-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma-Reference-Cited by-同舟云学术

The des-?-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma

Published:2003-12-04 Issue:12 Volume:98 Page:2671-2677
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Nagaoka Sakae,Yatsuhashi Hiroshi,Hamada Hisayuki,Yano Koji,Matsumoto Takehiro,Daikoku Manabu,Arisawa Kokichi,Ishibashi Hiromi,Koga Michiaki,Sata Michio,Yano Michitami

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference29 articles.

1. Plasma des-γ-carboxyprothrombin in the early stage of hepatocellular carcinoma

2. Usefulness of ED036 kit for measuring serum PIVKA-II levels in small hepatocellular carcinoma

3. Serum levels of des-?-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma

4. Prognostic significance of anatomical resection and des-γ-carboxy prothrombin in patients with hepatocellular carcinoma

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Construction of an immunosensor based on Cys/Au@TiO2 modification for the detection of liver cancer marker PIVKA-II;Talanta;2024-08

2. Impact of portal‐phase signal intensity of dynamic gadoxetic acid‐enhanced magnetic resonance imaging in hepatocellular carcinoma;Journal of Hepato-Biliary-Pancreatic Sciences;2023-08-07

3. Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy;Frontiers in Immunology;2023-02-23

4. The Characteristics and Prognosis of Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin Double-Negative Hepatocellular Carcinoma at Baseline in Higher BCLC Stages;Cancers;2023-01-06

5. HCC biomarkers – state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice;Frontiers in Oncology;2022-11-28